See more : Allied Gaming & Entertainment Inc. (AGAE) Income Statement Analysis – Financial Results
Complete financial analysis of InnoCan Pharma Corporation (INNPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InnoCan Pharma Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Toys”R”Us ANZ Limited (TOY.AX) Income Statement Analysis – Financial Results
- Salem Erode Investments Limited (SALEM.BO) Income Statement Analysis – Financial Results
- Lakshmi Electrical Control Systems Limited (LAKSELEC.BO) Income Statement Analysis – Financial Results
- Circassia Group Plc (CIR.L) Income Statement Analysis – Financial Results
- CNFC Overseas Fisheries Co.,Ltd (000798.SZ) Income Statement Analysis – Financial Results
InnoCan Pharma Corporation (INNPF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://innocanpharma.com
About InnoCan Pharma Corporation
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 13.66M | 2.56M | 196.00K | 8.00K | 0.00 | 0.00 |
| Cost of Revenue | 1.68M | 452.00K | 75.00K | 5.00K | 23.53K | 0.00 |
| Gross Profit | 11.98M | 2.11M | 121.00K | 3.00K | -23.53K | 0.00 |
| Gross Profit Ratio | 87.71% | 82.34% | 61.73% | 37.50% | 0.00% | 0.00% |
| Research & Development | 1.80M | 1.53M | 1.40M | 1.37M | 368.00K | 534.00K |
| General & Administrative | 3.08M | 3.98M | 3.71M | 2.90M | 2.44M | 593.00K |
| Selling & Marketing | 10.91M | 2.86M | 2.50M | 337.00K | 194.00K | 39.00K |
| SG&A | 13.99M | 6.85M | 6.20M | 3.24M | 2.63M | 632.00K |
| Other Expenses | -7.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.18M | 8.37M | 7.60M | 4.73M | 3.00M | 1.17M |
| Cost & Expenses | 9.85M | 8.83M | 7.68M | 4.73M | 3.00M | 1.17M |
| Interest Income | 23.42K | 21.00K | 13.00K | 8.00K | 40.00K | 0.00 |
| Interest Expense | 0.00 | 2.00K | 13.00K | 5.23M | 334.00K | 26.00K |
| Depreciation & Amortization | 33.61K | 33.61K | 42.62K | 42.11K | 23.53K | 2.00M |
| EBITDA | -3.77M | -3.70M | -7.44M | -4.69M | -2.98M | 0.00 |
| EBITDA Ratio | -27.60% | -242.67% | -3,794.39% | -58,562.50% | 0.00% | 0.00% |
| Operating Income | 3.80M | -6.27M | -7.48M | -4.73M | -3.00M | -1.17M |
| Operating Income Ratio | 27.85% | -244.86% | -3,816.33% | -59,062.50% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.84M | 2.38M | -2.61M | -5.23M | -334.00K | 806.86K |
| Income Before Tax | -4.03M | -3.89M | -10.09M | -9.95M | -3.34M | -1.19M |
| Income Before Tax Ratio | -29.54% | -151.93% | -5,148.47% | -124,412.50% | 0.00% | 0.00% |
| Income Tax Expense | 214.00K | 1.00K | -31.00K | -166.30K | -148.86K | -161.14K |
| Net Income | -4.70M | -3.76M | -10.05M | -9.95M | -3.34M | -1.19M |
| Net Income Ratio | -34.41% | -147.09% | -5,126.02% | -124,412.50% | 0.00% | 0.00% |
| EPS | -0.02 | -0.02 | -0.04 | -0.06 | -0.02 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.04 | -0.06 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 257.01M | 248.95M | 224.54M | 162.02M | 143.87M | 143.87M |
| Weighted Avg Shares Out (Dil) | 257.00M | 248.95M | 224.54M | 162.02M | 143.87M | 143.87M |
Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 14, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce today that a recent study conducted in mice based on Innocan's licensed...
Innocan Pharma Engages Lytham Partners to Lead Investor Relations and Shareholder Communication Program
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 10, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") today announced it has retained Lytham Partners, LLC ("Lytham Partners") to lead an investor relations and...
Innocan Pharma and Polyflame Announce an Exclusive Distribution Agreement in France
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 22, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the signing of a wide-scope commercial distribution agreement with Polyflame Europe. As...
Richard Serbin, Former Johnson & Johnson's VP and a Leading Global Strategy Advisor in the Healthcare Industry, to Join Innocan Pharma's Scientific Advisory Committee
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 6, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to announce the addition of Richard Serbin to its Advisory Committee. Richard Serbin will work...
Innocan Reports Q4 2020 Financial Results
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 1, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce today its financial results and business highlights for the fourth quarter and...
Leading American Dermatologist Dr. Mitchell Kline to Join Innocan Pharma's Scientific Advisory Committee
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") is proud to announce the addition of Dr. Mitchell Kline to its Scientific Advisory Committee....
Innocan Pharma Announces Proceeds of CDN $ 3.1M from the Exercise of Warrants Since January 1, 2021
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 16, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") today announces that since January 1, 2021, it has received proceeds of approximately CDN $3.1M...
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment
Herzlia, Israel and Calgary, Alberta--(Newsfile Corp. - March 10, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") filed an international patent application for a novel cannabis-based Anti-itch treatment. The composition is comprised...
Innocan Pharma Announces the Completion of its First Full-Scale Manufacturing Run in the US and the Launching of its US Commercial Online Platform
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 22, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan"), is pleased to announce the completion of its first full and large-scale commercial production of...
Innocan Pharma Announces Proceeds of CDN $ 1.8M from the Exercise of Warrants Since December 1, 2020
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - January 28, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") today announces that since December 1, 2020, it has received proceeds of approximately CDN $1.8M...
Source: https://incomestatements.info
Category: Stock Reports